A phase 1 study of a novel tau PET imaging agent [18F]APN-1607

APRINOIA Therapeutics Inc.1 个研究点目标入组 3 人开始时间: 待定最近更新: 2021年11月2日

适应症

试验速览

暂无简介。

•The subject is capable of understanding this clinical study and providing written consent to participate in this study.
•The subject is free of any disease potentially affecting his participation or assessments in the study on the basis of the examination at screening.
•The subject makes sure to use birth control for one week after study drug administration.

•The subject has a clinically significant abnormal value in the laboratory test at screening.
•The subject has known hypersensitivity to any ingredient of the study drug.
•The subject is intolerant of prolonged restraint on a bed of a PET scanner.
•The subject with poor venous access.
•The subject has history of evisceration that can interferes with calculation of absorbed dose.
•The subject received or plans to receive a barium swallow test within 2 weeks prior to study drug administration.
•The subject has received nuclear medicine test and exposed to radiation over 20 mSv within one year prior to study drug administration.
•The subject participated in the other interventional clinical study or research within three months prior to study drug administration.
•The subject, in the opinion of the investigator or co-investigator, is ineligible for participation in this study for any other reason.

safety Adverse events, laboratory test, vital sign and ECG

发起方

Loading locations...